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Introduction: Psychosis (delusions and/or hallucinations) is a well-recognized complication 
of treatment of Parkinson’s disease (PD). Quetiapine is a currently favored treatment, but data 
on its efficacy are equivocal. This trial aimed to provide further evidence on the efficacy of 
quetiapine in PD psychosis.
Methods: We conducted a 12 week double blind randomized placebo-controlled trial. Time 
to dropout due to lack of improvement of psychosis was the primary outcome measure. Other 
important secondary outcomes were evaluated using standard rating scales for PD and psychiatric 
symptoms.
Results: Twenty-four eligible subjects gave consent. The primary outcome, time to dropout, 
was examined using survival analysis. It was shown that patients in the quetiapine group dropped 
out earlier than those in the placebo group, but this difference was not significant (p = 0.68). No 
significant changes were found for any of the secondary outcome measures in either group.
Conclusions: In this study, quetiapine at doses of up to 150 mg/day failed to significantly 
improve psychosis compared to placebo, however the small sample size does not allow any con-
clusive interpretation of the results. Quetiapine did not appear to worsen PD motor functioning, 
but its use was limited by a faster drop out compared with placebo. Significant impediments 
were difficulty with recruitment and natural fluctuation in symptoms during the trial.
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Introduction
Psychosis (delusions and/or hallucinations) is a well-recognized complication of 
treatment of Parkinson’s disease (PD). A literature review gave the prevalence 
of hallucinations in clinic populations as between 8% and 44%.1 Risk factors for 
psychosis include older age, longer duration of disease, cognitive impairment, and 
sleep disturbance.1,2 Psychosis in PD is an indicator of poor prognosis and is frequently 
the deciding factor in necessitating nursing/institutional care.3,4
Until recently, managing psychosis in patients with PD posed clinicians with the 
“motion–emotion” dilemma: attempts to alleviate the psychosis, either by reducing 
antiparkisonian medication or introducing antipsychotic agents, led to worsening of 
the parkinsonian motor symptoms.5 The introduction of ‘atypical’ antipsychotic drugs 
into psychiatric clinical practice opened up a new range of therapeutic options. The 
most commonly used include clozapine, risperidone, olanzapine, and quetiapine. All 
have been used to treat psychosis in PD with varying success.6 Clozapine has been 
the most frequently evaluated to date with over 30 published reports. There have 
been two randomized placebo-controlled trials.7,8 Both studies showed significant Neuropsychiatric Disease and Treatment 2009:5 328
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improvements in psychopathology with no or minimal 
worsening in motor symptoms of PD. The main drawback 
of clozapine is the need for regular blood monitoring due 
to the risk of agranulocytosis (up to 1%). Initial reports of 
efficacy of risperidone and olanzapine were encouraging but 
subsequently these drugs were shown to worsen parkinsonian 
motor function.9,10
Quetiapine is one of the currently favored atypical 
antipsychotic treatments. It produces few parkinsonian 
side effects in patients with bipolar disorder and minimal 
increases in prolactin in patients with schizophrenia.11,12 
A systematic review revealed 10 reports of quetiapine use in 
PD psychosis involving 242 patients.13 Of these 191 (80%) 
were claimed to show improvement in psychosis and only 
25 (11%) worsening of motor symptoms. The most recent 
randomized placebo-controlled trials found no benefit of 
quetiapine.14–16
In an alternative approach, two small unblinded studies 
have directly compared quetiapine with the best alterna-
tive, clozapine. The first found both drugs to be equally 
efficacious.17 The other found clozapine had a significant 
advantage over quetiapine in reducing delusions, but showed 
only a nonsignificant trend over quetiapine in controlling the 
frequency of hallucinations.18 In addition one patient in the 
clozapine arm developed leukopenia. These data provide an 
incomplete and sometimes conflicting picture. This double-
blind randomized controlled trial attempted to provide further 
evidence on the efficacy of quetiapine in the management 
of PD psychosis.
Methods
We conducted a 12 week randomized, placebo-controlled 
double-blind clinical trial of quetiapine in PD psychosis. All 
patients met UK Brain Bank criteria for idiopathic PD. They 
were included if they suffered from either ‘hallucinations’, 
‘suspiciousness’, or ‘unusual thought content (delusions)’ 
of a severity 3/7, on the Brief Psychiatric Rating Scale 
(BPRS).19 Symptoms must have been present for over two 
weeks. Other inclusion criteria included: a reliable care-
giver; ability to assent to treatment; current antiparkinsonian 
treatment deemed to be optimal by the attending specialist 
consultants and communication ability sufficient to enable 
main assessments. Patients were recruited from the King’s 
College Hospital Regional Neurosciences Centre Move-
ment Disorder Clinic and outlying clinics led by consultant 
neurologists and geriatricians with specialist expertise in PD. 
The trial was pragmatic in the sense that clinicians had flex-
ibility regarding the antiparkinsonian regimen used, and 
also there were no exclusions based on age, dementia, or 
disease severity provided other practical inclusion criteria 
were met.
Exclusion criteria included current treatment with 
cholinesterase inhibitors, antipsychotic medication currently 
or in the preceding two weeks, any contraindication to 
quetiapine, important drug interactions, major concomitant 
medical illness, stroke or transient ischemic attack in the 
six months preceding assessment, uncontrolled diabetes or 
hypertension, uncontrolled atrial fibrillation or other cardiac 
arrhythmia, past drug/alcohol dependence, possible delirium 
and change in medication over the preceding two weeks 
(three weeks if cabergoline). Patients who had dementia with 
Lewy bodies were excluded.20 The protocol was approved 
by the local ethics committees and all subjects gave written 
informed consent/assent prior to the study.
Stopping rules enabled patients and their clinicians to 
withdraw from the study because of nonimprovement or 
clinically important worsening in psychiatric symptoms, and 
if found to be on placebo, for them to be offered open-label 
quetiapine as a first choice antipsychotic. This design was 
employed to address the issue of administering a placebo 
medication to symptomatic patients.
Those remaining on treatment under double-blind 
conditions were followed for a total of 12 weeks. From our 
experience with this clinical group we anticipated that few 
patients would be able to remain in a long trial under double-
blind conditions. Time remaining in the trial was therefore 
the primary outcome. This would give a measure of treatment 
efficacy as the design meant that patients would drop out if 
their psychosis failed to improve or deteriorated and would 
stay in if their symptoms were improving. As this was a 
pragmatic trial, time to drop out due to side-effects was also 
included in the analysis.
The main secondary outcome was improvement in 
psychotic symptoms. Other important secondary outcomes 
were evaluated using standard rating scales; the Unified 
Parkinson’s Disease Rating Scale (UPDRS), BPRS, Neuro-
psychiatric Inventory (NPI), and the Baylor PD hallucination 
scale.14,21,22
Power calculation was based of a 50% cessation of treat-
ment seen in the 12 week US clozapine study.7 We assumed 
that 50% of the quetiapine group and 90% of the placebo 
group would drop out of treatment by 12 weeks, generating 
87% power to detect time to drop-out as statistically different 
using a log-rank test with a two-sided significance level of 5% 
with 30 patients per group (total = 60). In the US clozapine 
study, the four-week mean BPRS for the placebo group was Neuropsychiatric Disease and Treatment 2009:5 329
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32.4 and for the clozapine group was 23.8. This represents a 
difference of 8.6 points. The pooled standard deviation was 
10.3, hence the standardized effect size is 0.835. This could 
be detected with 80% power (at 5% significance level) with 
24 per group in the current study.
Assessments were performed at 0, 2, 6, and 12 weeks. 
The study medications were randomized into quetiapine and 
identical appearing placebo by the manufacturers. Unblinding 
envelopes were held by the Clinical Trials Unit at the Institute 
of Psychiatry. Clinicians were free to increase or maintain 
dose of trial medication and identical-appearing placebo up 
to the beginning of the 6th week (after which it could be 
reduced if considered necessary due to side effects). The 
starting dose was 25 mg for week 1, 25 mg bd for week 2, 
50 mg bd for week 3, with an optional further increase to 
50 mg am, 100 mg nocte if clinically indicated.
Survival curves (Kaplan–Meier) were plotted for both 
groups. In addition the time to dropout was analyzed using 
the log rank test. Secondary outcome measures were analyzed 
using analysis of covariance. The significance level was 5% 
(two sided) for all analyses. Statistical analyses were per-
formed by the Statistics unit of the Institute of Psychiatry.
Results
Sixty-seven patients were screened over a 16-month period 
for a target of 60. After screening, a total of only 24 eligible 
subjects gave consent for enrolment. Eleven patients were 
randomized to quetiapine and 13 to placebo (Table 1). 
Thirteen patients completed six weeks in the double-blind 
part of the study (four quetiapine patients and nine placebo). 
Only eight patients completed the 12 week double blind 
(four from each group). Of those that dropped out, only five 
continued on open-label quetiapine. The mean dose in the 
quetiapine group was 72.7 ± 26.1 mg; in the placebo group 
it was 96.2 ± 32 mg.
Figure 1 shows the Kaplan–Meier survival functions 
of time to drop-out against cumulative survival. The graph 
shows that patients on quetiapine dropped out faster than 
patients on placebo. The log rank test was used to compare 
the survival distributions; they were not found to be signifi-
cantly different (p = 0.68). Quetiapine therefore did not have 
a significant effect on time to dropout.
Due to the small numbers and high drop out rate, the 
secondary outcome measures (Baylor PD hallucination 
scale, UPDRS, NPI, and BPRS) were only analyzed at six 
weeks. The analysis was by intention to treat and missing 
values were imputed using last observation carried forward. 
No significant changes were found for any of the secondary 
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outcome measures in either group. Importantly there was no 
significant effect of quetiapine on UPDRS scores, either on 
total score or motor subgroup (UPDRS III). This suggests 
that quetiapine at the doses used in the study did not worsen 
motor functioning in a clinically meaningful manner.
With regard to tolerability, three patients on quetiapine 
dropped out due to related adverse events (drowsiness). three 
patients on placebo also dropped out due to related adverse 
events (two drowsiness, one confusion).
Discussion
In this study we were not able to show that quetiapine at 
doses of up to 150 mg/day was able to significantly improve 
psychosis compared to placebo. Unlike some other atypical 
antipsychotics, quetiapine did not appear to worsen PD motor 
functioning. Its use was limited by a faster drop out compared 
with placebo, although this was not statistically significant.
Several features of the study may have limited the dem-
onstration of a significant antipsychotic effect. Firstly, these 
patients with longstanding PD appeared to show considerable 
day-to-day fluctuation in symptom severity, based on the rat-
er’s impressions at screening and baseline visits. This made 
accurate measurement of baseline severity and a change in 
clinical condition difficult. This problem may have been com-
pounded by the fact that we did not use a validated scale for 
PD psychosis as none was available at the start of the study. 
Both the BPRS and NPI are composite scales assessing many 
different neuropsychiatric symptom domains and therefore 
do not specifically assess psychosis. We performed separate 
analyses with the NPI hallucinations and delusions subscores, 
but there was still no difference between the two groups. The 
Baylor PD hallucination scale, an unvalidated scale designed 
for PD psychosis, revealed a trend towards improvement in a 
previous randomized controlled trial with quetiapine.14 How-
ever a similar trend was not seen in our study. There is now 
a partially validated scale for Parkinson’s disease psychosis 
which may be a useful tool in therapeutic intervention trials, 
though this remains to be tested.24
Secondly the doses used in the study may not have been high 
enough. The mean doses used were rather low compared to other 
studies (169 mg,14 119 mg,15 and 120 mg).16 It is possible that of 
inadequate dosage contributed to the result, however the trials 
using higher doses also showed no benefit of quetiapine.
Thirdly despite adequate screening and adequate power 
to the study design, we did not recruit the necessary number 
of patients in the time frame required. The major weakness 
of our study is the small sample size, a problem shared with 
two of the other published randomized controlled trials.14,16 
A significant factor affecting the recruitment rate was that 
many eligible patients referred for the study felt that their 
symptoms were not severe enough at the point of first inter-
view to warrant treatment (n = 18). However their opinion 
about the severity of their symptoms was often found to be at 
variance with that of their carers due to impaired insight. Such 
cases were referred back to their consultants for observation 
and re-referral if their symptoms worsened.
Another reason for slow recruitment was safety concerns 
(n = 11) regarding the use of antipsychotics in the elderly with 
dementia. Specific data in Parkinson’s disease patients are 
lacking, but there has been concern regarding the safety of the 
atypical antipsychotics in elderly patients with dementia. In 
2004 the Committee on Safety of Medicines (CSM) reviewed 
the data for risperidone and olanzapine.25 The evidence showed 
a three-fold increase in the risk of stroke for risperidone 
when used to treat behavioral disturbance in older patients 
with dementia. There was a similar risk with olanzapine The 
US Food and Drug Administration reported a similar increased 
risk between 1.6 and 1.7.26 Consequently a black box warning 
has been added to the label of all atypical antipsychotics in 
the US. The CSM and FDA advice was contained in the trial 
patient information sheet which limited recruitment.
Conclusion
In this pragmatic trial the time to dropout was the primary 
outcome measure. Quetiapine did not have a significant 
effect on time to dropout. There was also no significant effect 
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of quetiapine on any of the secondary outcome measures 
(BPRS, NPI, Baylor PD hallucination scale, and UPDRS). 
The small sample size of the study does not allow any 
conclusive interpretation of the results.
This trial has not answered the question of whether 
quetiapine is an effective treatment for PD psychosis. How-
ever, it has highlighted the difficulties in attempting to design 
and conduct such a placebo-controlled trial in a clinically 
meaningful and pragmatic manner. A significant impedi-
ment to performing the trial was the difficulty in quantifying 
clinically significant changes in symptom severity due to 
fluctuation of symptoms and the lack of a validated scale. 
Recruitment into the trial was slow due to safety concerns 
regarding the use of atypical antipsychotics in the elderly. 
In addition the doses of quetiapine used in the study were 
rather low which may have prevented any demonstration of 
antipsychotic effect. The effective treatment of psychosis in 
PD is still an urgent clinical need.
The absence of an effect of quetiapine on motor functioning 
was noted, as has been previously reported.14–16
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